Effective June 3, 2024, Propanc Biopharma, Inc. entered into and closed a loan agreement with an investor, pursuant to which the First Investor loaned the Company an aggregate principal amount of $20,000 AUD. The Company intends to use the net proceeds therefrom for general working capital purposes. The maturity date of the First Loan is June 3, 2025, or sooner at the discretion of the Company, and the First Loan bears an interest rate of (12%) per annum.

The Company has the right to prepay in full at any time with no prepayment penalty. Effective June 5, 2024, Propanc Biopharma, Inc. entered into and closed a loan agreement with an investor, pursuant to which the Second Investor loaned the Company an aggregate principal amount of $100,000. The Company intends to use the net proceeds therefrom for general working capital purposes. The maturity date of the Second Loan is June 5, 2025, or sooner at the discretion of the Company, and the Second Loan bears an interest rate of (12%).

The Company has the right to prepay in full at any time with no prepayment penalty.